Clinical trial · Observational
RASi for Preventing Postoperative Recurrence of Stage II/III Colon Cancer
Renin-angiotensin System Inhibitor for Preventing Postoperative Recurrence of Stage II/III Colon Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this retrospective cohort study is to learn about the long-term effects of renin-angiotensin system inhibitors (RASi) in preventing patients with hypertension and stage II/III colon cancer from recurrence and metastases after radical resection. The main question it aims to answer is: Does RASi improve the 3-year disease-free survival of patients with hypertension and stage II/III colon cancer after surgery? Participants with hypertension and already having radical resection of stage II/III colon cancer will be followed up for 3 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer (Stage II &Amp;Amp; III) | Malignant Colon Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No renin-angiotensin system inhibitors (No RASi) | Drug | — | UNRESOLVED |
| Renin-angiotensin system inhibitors (RASi) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Renin-angiotensin system inhibitors (RASi)
- description
- Using RASi after radical resection of stage II/III colon cancer
- interventionNames
- Drug: Renin-angiotensin system inhibitors (RASi)
- label
- No renin-angiotensin system inhibitors (No RASi)
- description
- Not using RASi after radical resection of stage II/III colon cancer
- interventionNames
- Drug: No renin-angiotensin system inhibitors (No RASi)
Primary outcomes (1)
- measure
- 3-year disease-free survival
- timeFrame
- 3 years after surgery
- description
- The events of 3-year disease-free survival are defined as any recurrence of metastases or death within 3 years after surgery.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Inferior tumor edge \> 15 cm from anal verge; 2. Received radical resection of primary tumor; 3. Pathological proved stage II or stage III adenocarcinoma; 4. No evidence of distant metastases at time of surgery (including pelvis, peritoneum, liver, lung, brain, bone, distant lymph node, etc), according to ultrasound, CT, MRI, PET-CT, intraoperative exploration, etc; 5. Combined with hypertension at time of surgery; 6. No other malignancies in medical history except adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri; 7. Informed consent. Exclusion Criteria: 1. Emergency surgery for acute intestinal obstruction, bleeding, perforation, etc; 2. Multiple primary colorectal cancer; 3. Hereditary colorectal cancer (familial adenomatosis polyposis, Lynch Syndrome, etc.); 4. Co-existent inflammatory bowel disease; 5. Pregnancy or lactation; 6. Received any of preoperative anti-cancer treatment.
References
Publications (0)
Data not yet available